Navigation Links
MIGENIX Reports Third Quarter Fiscal Year 2008 Financial Results
Date:3/13/2008

cond quarter of 2008, with results available in the second half of 2008 and if the results of this trial are positive, Cadence submitting a new drug application (NDA) for Omigard(TM) in the first half of 2009; our plans to add approximately six patients at 600 mg dose in the celgosivir Phase II viral kinetics study and having results from the study in the third quarter of 2008; Cutanea Life Sciences' plans to advance omiganan for the treatment of rosacea into Phase III clinical development in 2008, our estimate of the probable royalties payable to the holders of the convertible royalty participation units; our plans to advance MX-2401 into the clinic in late 2009; Spring Bank's plans to advance the SB 9000 program into the clinic in 2009; the Company continuing to advance its highest priority programs while operating within an annual burn rate of $9 million to $10 million; and the Company's financial resources being sufficient to fund operations into the fourth quarter of 2008.

With respect to the forward-looking statements contained in this news release, we have made numerous assumptions regarding, among other things: Cadence's ability to enroll sufficient patients to complete the Omigard(TM) Phase III trial; the adequacy of the Omigard(TM) Phase III trial design to generate data that are deemed sufficient by regulatory authorities to support potential regulatory filings, including an NDA, for Omigard(TM); our ability to enroll approximately six patients at the 600 mg dose in the celgosivir Phase II viral kinetics study and having results from the study in the third quarter of 2008; Cutanea's ability to manage, fund and advance omiganan for dermatological applications into Phase III, the adequacy of Cutanea's Phase II results for regulatory authorities to support advancing to Phase III; Spring Bank's ability to manage, fund and advance SB 9000 into clinical development; our ability to manage licensing opportunities; our ability to initiate, fund and complete
'/>"/>

SOURCE MIGENIX Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related biology technology :

1. MIGENIX Third Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification
2. MIGENIX releases CEO message #22
3. MIGENIX to Add 600mg Daily Celgosivir Dose to Phase II Viral Kinetics Study
4. MIGENIX Reports Second Quarter Fiscal Year 2008 Financial Results
5. MIGENIX Second Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification
6. MIGENIX to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
7. MIGENIX Reports First Quarter Fiscal Year 2008 Financial Results
8. MIGENIX to Present Positive Celgosivir Viral Resistance Data at International HCV Meeting
9. MIGENIX First Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification
10. Nventa Biopharmaceuticals Reports Full Year 2007 and Fourth Quarter Financial Results
11. Micromet, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... SAN DIEGO , Sept. 16, 2014  Biocom, ... life science community, recognizes the 9 th ... to the value of IT technologies in improving our ... California is one of the world,s most ... from EHRs to mobile health applications to genomic testing ...
(Date:9/16/2014)... created a deicing film for radar domes have now ... for glass. , The new work by Rice ... surfaces from windshields to skyscrapers free of ice and ... , The technology was introduced this month in ... Interfaces . , The material is made of ...
(Date:9/16/2014)... Fresne, President and CEO of Egenix, Inc. is pleased to ... its Scientific Advisory Committee. Dr. Vagner, a graduate ... performed research at Embl (European Molecular Biology Laboratory) Heidelberg, ... of health and medical research. He is a Research Director ... France , and at the Gustave Roussy ...
(Date:9/16/2014)... Sept. 16, 2014   Synthetic Biologics, Inc. ... novel anti-infective biologic and drug programs targeting specific ... the completion of the Company,s Investor Day in ... its irritable bowel syndrome (IBS) program, including its ... In the keynote presentation, Mark ...
Breaking Biology Technology:Biocom Recognizes National Health IT Week 2Nanoribbon film keeps glass ice-free 2New Appointment to the Scientific Advisory Committee at Egenix, Inc. 2Synthetic Biologics' Statin-Class Candidate for Constipation-Predominant Irritable Bowel Syndrome Detailed at Company's Investor Day 2Synthetic Biologics' Statin-Class Candidate for Constipation-Predominant Irritable Bowel Syndrome Detailed at Company's Investor Day 3
... conjunction with,CorVel Corporation,s (Nasdaq: CRVL ) quarterly earnings release, CorVel will,be ... Tuesday, August 5th at 11:30 am Eastern Time., Event: ... Dan Starck, President and CEO ... 11:30 am Eastern Time, Tuesday, August ...
... Researchers at Fred Hutchinson Cancer,Research Center have received ... Genome Research Institute to better understand the genetic,and ... is one of,four U.S. research institutes to receive ... The Hutchinson Center project, led by biostatistician and ...
... MOUNTAINSIDE, N.J., July 17 National Stem,Cell Holding, ... owned,subsidiary Proteoderm, Inc. is exhibiting at the 16th ... in Washington, DC on July,17 -- 19, 2008. ... speak as a,scientific keynote panelist. Dr. Steiner will ...
Cached Biology Technology:CorVel Corporation Announces Earnings Release Webcast 2Hutchinson Center Receives $7.6 Million Federal Grant to Study How Genetic Variations Influence Risk of Common Diseases 2Hutchinson Center Receives $7.6 Million Federal Grant to Study How Genetic Variations Influence Risk of Common Diseases 3National Stem Cell Holding, Inc. (Ticker NHGI) Subsidiary Proteoderm, Inc. Debuts Cosmoceutical Line at the 2008 World Congress on Anti-Aging Medicine 2
(Date:9/15/2014)... epilepsy drug to a morphine regimen can result in ... combination can reduce the dosage of the opioid needed ... researchers at Indiana University. , The result could bring ... difficult-to-treat condition often felt in the arms and legs ... a huge unmet need for better treatments for neuropathic ...
(Date:9/15/2014)... for both plants and animals alike. , Understanding just ... lead to the design of better drugs for diabetes ... and vegetables farmers are able to grow. Stanford University ... the cell by piecing together proteins slightly wider than ... To determine the size, shape and orientation of one ...
(Date:9/15/2014)... When this week,s print issue of the journal ... up from New Mexico, Montana and even the Netherlands, ... more and more the norm in these connected times. ... it will produce innovations in biology, medicine, biotechnology and ... this scientist talked with that one, that one knew ...
Breaking Biology News(10 mins):IU study: Combining epilepsy drug, morphine can result in less pain, lower opioid doses 2X-rays unlock a protein's SWEET side 2X-rays unlock a protein's SWEET side 3Collaboration drives achievement in protein structure research 2
... Each year, millions of monarch butterflies ( Danaus ... to colonize eastern North America, but just how these ... their breeding range in spring has largely remained a ... Guelph led by Prof. Ryan Norris, Department of Integrative ...
... musculus ) happily live wherever there are humans. When ... them. New research published in BioMed Central,s open access ... techniques on modern day and ancestral mouse mitochondrial DNA ... that of Viking invasion. During the Viking age ...
... Calif., March 18, 2012 Autoimmune diseases, such as ... an immune system gone haywire, where the body,s defense ... of a protein called LYP has been implicated in ... has been unknown. Now, in a paper published March ...
Cached Biology News:Study reveals how monarch butterflies recolonize northern breeding range 2The Viking journey of mice and men 2New insight into mechanisms behind autoimmune diseases suggests a potential therapy 2
... optically clear polystyrene with frosted labeling ... for cell counting. 100% integrity tested. ... new product number, created to easily ... no availability yet, please order under ...
Packaging: package with 500 l Patent/trademark/license (electronic): (r) Registered trademark of Molecular Probes...
... VersaDoc MP 4000 System is a ... system capable of supporting a wide ... chemiluminescence, densitometry, and chemiflourescence. Red, ... imaging of multiplexed fluorescent samples, reducing ...
... hydrophobic barrier pen for immunohistochemistry and in ... frozen or paraffin-embedded tissue sections mounted on ... heat-stable, water-repellent barrier that keeps staining reagents ... of reagents when differentially staining two sections ...
Biology Products: